Extending its efforts in the booming antibody-drug conjugate (ADC) space, Beigene Co. Ltd. tapped Duality Biologics Co. Ltd. in a deal that could be worth a potential $1.3 billion, picking up an option for rights to a preclinical-stage ADC candidate targeting select solid tumors. It marks the seventh $1 billion-plus ADC-focused deal so far in 2023 and the second for Dualitybio, which inked a potential $1.7 billion deal in April.
Itabmed Ltd. received an IND approval to start a phase I trial of its CD3-activating bispecific antibody A-337 for the treatment of patients with advanced solid tumors.
TG Immunopharma Co. Ltd. has announced clearance by the FDA for a clinical trial of TGI-6, a bispecific antibody targeting unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, for solid tumors.
Itabmed Ltd. received an IND approval to start a phase I trial of its CD3-activating bispecific antibody A-337 for the treatment of patients with advanced solid tumors.
CSPC Pharmaceutical Group Ltd. has received clinical trial clearance by China’s National Medical Products Administration (NMPA) for SYH-2051 for solid tumors.
Lantern Pharma Inc. has received IND clearance from the FDA for LP-184, which is being developed for advanced solid tumors and central nervous system (CNS) cancers.
C4x Discovery Holdings plc has announced further progress in its MALT1 inhibitor program for cancer. Building on anti-cancer activity in a preclinical xenograft study, the company completed a preclinical study demonstrating its MALT1 lead compounds were free of UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) liability shown by competitor chemistries. The program is continuing to identify a shortlist of preclinical candidates for further development, and a partnering program has been initiated.
